Determinants of adherence to ARVs in HIV+ women enrolled in the  PMTCT program in the West and North Regions of Cameroon by Tiotsia Tsapi, Armand et al.
Tiotsia Tsapi et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2021; 11(1-s):62-70 
ISSN: 2250-1177                                                                                      [62]                                                                                         CODEN (USA): JDDTAO 
Available online on 15.02.2021 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-21, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use(CC By-NC), provided the original work is properly cited 
Open  Access  Full Text Article                                                                                                                                      Research Article  
Determinants of adherence to ARVs in HIV+ women enrolled in the 
PMTCT program in the West and North Regions of Cameroon 
Armand Tiotsia Tsapi*1,2, Eric Defo Tamgno2,3, Eméline Zogning Makemjio2,4, Ezechiel Ngoufack Jagni 
Semengue2,4,5, Ghyslaine Bruna Djeunang Dongho1, Efeutmecheh Sangong Rose6, Hervé Davy Tongue Kamga2, 
Georges Nguefack-Tsague8, Gianluca Russo1, Martin Sanou Sobze7 
1 Department of Infectious Diseases, Microbiology and Public Health; Sapienza University of Rome, Rome, Italy. 
2 Faculty of Sciences and Technology, Evangelical University of Cameroon, Bandjoun, Cameroon. 
3 Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium. 
4 Department of experimental medicine, University of Roma Tor Vergata, Rome, Italy 
5 Chantal Biya International Reference Center, for research on HIV prevention and management, Yaoundé, Cameroon  
6 Regional Technical Group for the Fight against HIV/AIDS, Northwest Region, Cameroon  
7 Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon 




Received 10 Dec 2020;       
Review Completed 22 Jan 2021 
Accepted 02 Feb 2021;    
Available online 15 Feb 2021   
_____________________________________________ 
*Address for Correspondence:   
Armand Tiotsia Tsapi,  
1 Department of Infectious Diseases, Microbiology and 
Public Health; Sapienza University of Rome, Rome, Italy. 
2 Faculty of Sciences and Technology, Evangelical 
University of Cameroon, Bandjoun, Cameroon. 
________________________________________________________________ 
Cite this article as:  
Tiotsia Tsapi A, Defo Tamgno E, Zogning Makemjio E, 
Ngoufack Jagni Semengue E, Djeunang Dongho GB, 
Sangong Rose E, Tongue Kamga HD, Nguefack-Tsague G, 
Russo G, Sanou Sobze M, Determinants of adherence to 
ARVs in HIV+ women enrolled in the PMTCT program in 
the West and North Regions of Cameroon, Journal of 
Drug Delivery and Therapeutics. 2021; 11(1-s):62-70                                                                      
DOI: http://dx.doi.org/10.22270/jddt.v11i1-s.4712                
Abstract 
______________________________________________________________________________________________________ 
Background: According to UNAIDS 2019, 52% of people worldwide living with HIV is on 
antiretrovirals (ARVs), HIV positive women representing 80% of them. This study aimed 
at highlighting the determinants of adherence to ARVs for HIV positive women enrolled 
in PMTCT programs in the West and North Regions of Cameroon. 
Methods: A descriptive and analytical cross-sectional study was carried out from 
February to September 2019 in three treatment centres in the West (Bafoussam Regional 
Hospital and Dschang District Hospital) and North (Garoua Regional Hospital) regions in 
Cameroon. Data were collected using a questionnaire administered face to face and 
encoded in Excel 2013, then analyzed using SAS version 7.8. P-values < 0.05 were 
considered statistically significant 
Results: One thousand (1000) women were interviewed. The mean age was 17 ±2 years 
(Range: 12 – 67 years); 231 (23.1%) were single. Overall, the prevalence of ART-
adherence was 68.6%. After multivariate analysis using multiple logistic regression; 
having one HIV-infected children (aOR=60.9; 95%CI=[7.6; 489.1]; P=0.001), non-
disclosure of serological status with the spouse/boyfriend (aOR=25.2; 95%CI=[9.2; 68.9]; 
P<0.001), not being educated (aOR=7.7; 95%CI=[4.4; 13.3]; P<0.001); and taking ARVs 
once or less daily (aOR=50; 95%CI=[20.0; 100.0]; P<0.001) were four risk factors for non-
adherence. 
Conclusion: ART-adherence among Cameroonian pregnant women is still very far below 
UNAIDS target (95%), with four potential key determinants identified. As we are 
progressively moving towards the elimination of HIV vertical transmission in 2030 as 
advocated by UNAIDS, local policies should be reinforced in order to consolidate the 
strides made so far. 
Keywords: HIV, PMTCT, Pregnancy, Adherence, option B+, Cameroon. 
 
INTRODUCTION 
In line with the multiple efforts undertaken to improve 
access to antiretroviral drugs (ARVs) in sub-Saharan Africa, 
ARV coverage among people living with HIV (PLWHIV) in 
Cameroon has increased from 0% in 2003 to 22% in 2014. 
However, the success of HIV programs does not depend 
exclusively on access to ARVs, but also on retention in care 
and adherence to ARVs. This is critical to achieving viral load 
suppression, preventing the emergence of new HIV resistant 
strains, reducing transmission and the number of HIV-
related deaths 1. The use of antiretroviral therapy (ART) is a 
fundamental strategy proposed by the World Health 
Organization (WHO) for the prevention of mother-to-child 
transmission (PMTCT) of HIV 2. This strategy has led to a 
considerable reduction in the morbidity and mortality rates 
associated with HIV/AIDS 3. In 2019, 37.9 million (32.7 
million-44.0 million) people were living with HIV 
worldwide. These included 36.2 million (31.3 million-42.0 
million) adults and 1.7 million (1.3 million-2.2 million) 
children (<15 years). In 2010, 23.3 million (20.5 million-24.3 
million) people living with HIV had access to antiretroviral 
treatment, but only 54% (37-73%) of children aged 0-14 
years and 68% (52-82%) of adult women aged 15 years and 
older had access to treatment 4. 
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Sub-Saharan Africa has the highest burden of HIV in the 
world. Guidelines and programs for HIV prevention plans 
should be designed following an assessment of the cost-
effectiveness of country-level activities, with the aim of 
contextualizing interventions to achieve much better results 
5. Despite the fact that significant progress has been made in 
eliminating mother-to-child transmission of HIV in sub-
Saharan Africa, much remains to be done 6. In 2019, in 
Cameroon, 540 000 people were living with HIV. The 
incidence of HIV among the population during that year was 
1.02% for all age groups combined. HIV prevalence, that is, 
the percentage of people living with HIV, was 3.6% among 
adults (between 15 and 49 years). 23,000 new HIV 
infections were registered. 18 000 people died of HIV-
related causes. Antiretroviral coverage among pregnant 
women living with HIV to prevent transmission of the virus 
to their children was 80%, preventing 4,200 new infections 
among newborns. The rate of early infant diagnosis, that is, 
the percentage of HIV-exposed babies tested before their 
eighth week of age, reached 61% in 2018 7. 
The most highlighted barriers to achieving PMTCT of HIV are 
late initiation of antiretroviral treatment, non-adherence 
and non-involvement of men in the process. Hence, the need 
to implementing the 90-90-90 goals for the elimination of 
MTCT is imperial 8,9. However, because HIV-infected 
pregnant women experience a great psychological crisis, 
health care providers need to use an approach that is as 
user-friendly as possible 10. 
Many studies conducted in different regions of Cameroon 
show some disparity in the prevalence of adherence to ARVs 
among PMTCT women. For example, a prevalence of 
adherence to ARVs of 65.2% was reported in the study 
conducted by Tebeu et al. in the Health Districts of Ndop and 
Fundong, North West Region of Cameroon 11, another of 
67.5% in 2012 in the study by Perfura et al., at the Jamot 
Center in Yaoundé 12, and finally a prevalence of 62.7% in 
the Kumbo Health District 13; compared to a prevalence of 
87.1% in Ethiopia 14. Similarly, several studies conducted in 
Cameroon and sub-Saharan Africa show that demographic 
and socio-economic factors, patient-related factors, factors 
related to health care systems and ART, stigmatization, 
transportation costs, deprivation of food and whether or not 
the woman's HIV status is shared with her partner, family 
and community, educational level, occupation, and lack of 
knowledge of the spouse's HIV status can positively or 
negatively influence adherence to ART for HIV-positive 
women 1–3,11–15. 
However, the factors that impede adherence to 
antiretroviral treatment in Cameroon are not well known 
and may be influenced by the specific lifestyle habits of each 
Cameroonian region. For a much better efficiency of local 
ARVs programs, it is essential to identify barriers to 
adherence and then determine and implement appropriate 
measures to promote and improve it. 
MATERIALS AND METHODS 
This was a cross-sectional descriptive and analytical study 
conducted from February to September 2019 in three 
treatment centres of PLWHIV, belonging to the Western 
(Bafoussam Regional Hospital and Dschang District 
Hospital) and Northern (Garoua Regional Hospital) regions. 
This study aimed to highlight the determinants of adherence 
to ARVs among a cohort of women followed within the 
aforementioned healthcare facilities in PMTCT programs. 
Data was collected using a questionnaire administered face-
to-face to all PMTCT women who came for consultations or 
for ARV supplies during our survey. The minimum sample 
size for our study was calculated using the standard formula 
for cross sectional studies 16 which resulted in 395 women. 
Once collected, the data were entered and processed using 
Excel 2013 software and analyzed using SAS version 7.8 
software. 
From the descriptive analysis, we extracted frequencies and 
proportions. Adherence to treatment was assessed by 
combining two methods. The direct method taking into 
account clinical parameters such as CD4 count (≥ 350 CD4), 
Viral Load (≤ 50 copies) and the indirect method taking into 
account the intrinsic elements of the patient like the 
therapeutic protocol, the absence of annoying post-
medication manifestations. A patient with a positive score 
(greater than or equal to 3) to both methods was declared 
adherent. Univariate analyses were carried out using a Chi 
square test and multivariate analyses by the binary logistic 
regression method using adherence or non-adherence to 
treatment as the dependent variable. A significance level of 
0.05 and odds ratio value compared to the number one (1) 
allowed us to decide on the relationship between the 
variable of interest (adherence) in our study and the 
independent variables. For the profession, we have divided 
it into three sectors, namely primary (farmer, housewife, 
other without qualification), secondary (craftsman, 
merchant) and tertiary (civil servant, retired). 
Ethical approval: To conduct this study, we obtained the 
ethical approval Number CEN°158/CRERSH/2019 of the 
Center Regional Committee for Ethics and Research in 
Human Sciences. 
Consent of participants: In this study, informed written 
consent was obtained from each participant, prior to his 
inclusion in the study. 
RESULTS 
Socio-demographic Features 
A total of 1000 women equally distributed in the West and 
North Regions of Cameroon (500 women per region) took 
part in this study. According to age, women participating in 
this study were relatively young ([12 - 34] years); with very 
few among them (26%; 260/1000) living in rural areas. 
According to ethnicity, the bamileké women were more 
represented (57.2%; 572/1000) and 72.4% (724/1000) 
women in our study population were Christian women. 
About 18.4% (184/1000) participants never went to school 
and where thus considered as not-educated. According to 
civil status, we counted 44.4% (444/1000) single women, 
47.5% (475/1000) married, 3.9% (39/1000) divorced and 
4.2% (42/1000) widows. Among the married women, 
48.21% (229/475) belonged to a polygamous home. As 
regarding the legal spouses (for the married women) and 
the boyfriends (for both the single, the divorced and even 
some widows) about 23.69% (218/920) of them were HIV-
negative.  Finally, 25.2% (252/1000) of women declared not 
having any children while 36.5% (365/1000) declared to 
have more than four living children; among all these living 
pregnancies, 8.82% (66/748) women only had at least one 
HIV-infected children; with a median age of 3 [interquartile 
range: 0.5 - 6] years old for these infected children. Table1 
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Table 1: Socio-demographic characteristics of sampled PMTCT women 
Variables Term and Conditions Total Percentages 
Age (N=1000) 
[12-34]  727 72.7 
[35-67] 273 27,3 
    
Residential Area (N=1000) 
Rural Areas 260 26 
Urban Areas 188 18.8 
Semi-urban Areas 552 55.2 
    
Ethnicity (N=1000) 
Bamiléké 582 58.2 
Foufouldé 81 8.1 
Toupouri 241 24,1 
Haoussa 96 9.6 
    
Religion (N=1000) 
Christian 724 72.4 
Muslim 179 17.9 
Other 97 9.7 
    
Level of Education 
(N=1000) 
Not educated 184 18.4 
Primary 352 35.2 
Secondary 359 35.9 
University 105 10.5 
Civil Status (N=1000) 
Single 444 44.4 
Married 475 47.5 
Divorced 39 3.9 
Widow 42 4.2 
    
Matrimonial regime 
(N=475) 
Polygamous 229 48.21 
Monogamous 246 51.79 
    
HIV status of the partners 
(N=920) 
Positive  616 67.0 
Negative  218 23.7 
Unknown  86 9.3 
    
Number of Children 
(N=1000) 
No children 252 25.2 
1 child 173 17.3 
2-4 children 210 21.0 
Above 4 children 365 36.5 
    
Number of HIV-infected 
Children (N=748 women) 
None  682 91.2 
1 HIV(+) child 37 4.9 
More than 1 HIV(+) child 29 3.9 
    
Profession (N=1000) 
Primary sector 728 72.8 
Secondary sector 203 20.3 





Tiotsia Tsapi et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2021; 11(1-s):62-70 
ISSN: 2250-1177                                                                                      [65]                                                                                         CODEN (USA): JDDTAO 
Social behaviours and others parameters 
Disclosure of the serological status with spouse/boyfriend 
and family members was not systematic in the study 
population; about 21.7% (217/1000) and 44% (440/1000) 
women respectively had not disclosed their serological 
status in either case. Similarly, 34.4% (344/1000) and 
29.4% (294/1000) of the spouses and other family members 
respectively were not informed of their treatment. As a 
result, 35.1% (351/1000) of the women interviewed did not 
receive support from family members. (See table 2 for more 
clarifications)
 
Table 2: Disclosure of the serological status with the family 
Characteristics Total Percentage (%) 
Disclosure of the status with spouse/boyfriend (N=1000)  
Yes 783 78.3 
No 217 21.7 
Spouse informed of the treatment (N=1000)  
Yes 656 65.6 
No 344 34.4 
Disclosure of the status with other family members (N=1000)  
Yes 560 56 
No 440 44 
Other members (friends) aware of your treatment? (N=1000)  
Yes 706 70.6 
No 294 29.4 
Do you receive support from these members (N=1000)  
Yes 649 64.9 
No 351 35.1 
 
Antiretroviral therapy and treatment outcomes 
Respectively 2.4% (24/1000) and 3.7% (37/1000) of the 
women surveyed admitted having difficulties meeting the 
doctor responsible for their clinical follow-up and having 
difficulties meeting the pharmacist in charge of dispensing 
ARVs. However, all (100%) of them declare that they get 
help from their doctors and care providers when necessary 
and are satisfied (99.6%) with the advice given by health 
workers to facilitate their experience with the disease. 
(Table 3). 
 
Table 3: PMTCT woman interaction with care providers 
Characteristics Total Percentage (%) 
Difficulties in meeting the Doctor (N=1000)  
Yes 24 2.4 
No 976 97.6 
Getting help when needed (N=1000)  
Yes 1000 100 
No 0 0.0 
Satisfaction with advice given by Health Workers (N=1000)  
Yes 996 99.6 
No 4 0.4 
Difficulty meeting the Pharmacist (N=1000)  
Yes 37 3.7 
No 963 96.3 
Member of an association of PLWHIV? (N=1000)  
Yes 562 56.2 
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About 94.2% (942/1000) of the women enrolled were under 
a first line regimen (2 nucleoside reverse transcriptase 
inhibitors + 1 non-nucleoside reverse transcriptase 
inhibitors). Only 12.1% (121/1000) of them had a viral load 
of less than 50 copies/ml and 13.9% (139/1000) were found 
with a CD4 count of more than 350 cells/mm3.  
Embarrassing manifestations at the initiation of ART 
treatment were encountered in 71.4% (714/1000) of the 
women surveyed. Vomiting [13% (130/1000)] and dizziness 
[11.9% (119/1000)] were the most frequently reported 
symptoms of discomfort after ARV treatment, and these 
decreased in 20.1% (201/1000) of cases as the drugs were 
taken. Among our respondents, 52.5 (525/1000) had 
initiated antiretroviral treatment at least 36 months before 
our survey and 2.4% (24/1000) of them were taking 
between two (02) and four (04) ARV tablets per day. Finally, 
91% (910/1000) of these women reported a remarkable 
improvement in their health during the course of the 
medication. (See table 4 for more clarifications) 
 
Table 4: Antiretroviral therapy and treatment outcomes 
Characteristics Total Percentage (%) 
Therapeutic protocol (N=1000)  
1st line 942 94.2 
2nd line 58 5.8 
Viral load (N=1000)  
≤ 50 copies 121 12.1 
> 50 copies 879 87.9 
CD4 count (N=1000)  
≤ 350 861 86.1 
> 350 139 13.9 
ART initiation date (N=1000)  
Less than 12 months 107 10.7 
12-24 months 197 19.7 
24-36 months 171 17.1 
More than 36 months 525 52.5 
Number of ART tablets per day (N=1000)  
One (01) tab 806 80.6 
Two (02) tabs 170 17.0 
2-4 tabs 24 2.4 
Embarrassing post-medication events (N=1000)  
Vomiting  130 13.0 
Vertigo  119 11.9 
Asthenia  11 1.1 
All of the above 16 1.6 
Nothing 720 72.0 
Other 4 0.4 
Evolution of trouble some manifestations with 
medication (N=1000) 
 
Nothing 720 72.0 
Decrease 207 20.7 
Increase 2 0.2 
No change 71 7.1 
Improvement in health since treatment (N=1000)  
remarkable Improvement 910 91.0 
No Improvement 90 9.0 
Treatment interruption in the previous year (N=1000)  
Yes 119 11.9 
No 881 88.1 
Knowledge of the risks of non-medication (N=1000)  
Yes 759                75.9   
No 241 24.1 
 
It was found that 99.2% (992/1000) of the women 
interviewed contributed in a way or another to their care. 
About 74.1% (741/1000) of their contribution was much 
more related to the cost of transportation to the healthcare 
facility and the purchase of drugs for opportunistic 
infections. The monthly contribution quota most frequently 
mentioned was included in the range of 0-5000 Fcfa [64.2% 
(642/1000)]. However, 57.5% (575/1000) of the 
respondents considered this cost to be affordable, as long as 
it allowed them to regain their health (table5). 
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Table 5: Contribution to the therapeutic process 
Characteristics Total Percentage (%) 
Contribution to Treatment (N=1000)  
Yes 992 99.2 
No 8 0.8 
Elements to Contribute for the Treatment (N=992)  
Transport (T) 144 14.52 
Analysis Fees (AF) 6 0.6 
Transport and Analysis Fees 61 6.15 
Transport and purchase of drugs (against opportunistic infections) 741 74.7 
All of the above 40 4.03 
Cost of contribution (N=992)  
0-5000 FCFA 642 64.72 
5000-10000 FCFA 170 17.14 
> 10000 FCFA 180 18.14 
Appreciation of the burden of the contribution (N=1000)  
High 276 27.6 
Affordable 575 57.5 
Good 149 14.9 
 
Overall prevalence of adherence to ARVs 
Combining both direct and indirect methods described 
above, we came out with a general prevalence in terms of 
adherence to antiretroviral treatment of around 69.6% 
(696/1000). Data collected from these women reveal a 
higher prevalence of adherence to antiretroviral therapy in 
the North Region than in the West; with respective values of 
74.0% (370/500) and 63% (315/500). Three reasons were 
given by our respondents to justify non-adherence: 
forgetfulness (80.5%), fear of the spouse/boyfriend (12.0%) 
and drug stock out (7.5%). 
 
Table 6: Monitoring of ART- adherence 
Characteristics Total Percentages (%) 
Reasons for Non-adherence to ART (N=1000) 
Forgetfulness 805 80.5 
Fear of the spouse 120 12.0 
Drug stock out 75 7.5 
 
 
Key determinants of non-adherence 
With the use of univariate analysis, we were able to come out 
with 9 key determinants of non-adherence. The region of 
residence, the level of education, the civil status and 
matrimonial regime (for the married women in particular), 
disclosure of serological status, the number of HIV-infected 
children, the frequency of ARVs uptake per day, the 
immunological status and finally the level of viral 
suppression; all showed a statistical significance with respect 
to non-adherence. As for the region of residence and the 
marital status, being from the North region or from a 
polygamous home were risk factors of non-adherence 
(p<0.001, OR=1.67 and p<0.001, OR=2.54 respectively). 
Being educated, married, having more than one HIV-infected 
child and the disclosure of serological status were found to 
be protective socio-demographic parameters (p<0.001, 
OR=0.31; p<0.001, OR=0.16; p=0.002, OR=0.10; and p<0.001, 
OR=0.12 respectively). One time ARVs uptake per day, CD4 > 
350 cells/mm3 and viral load < 40 RNA copies/ml were also 
found to protect against non-adherence within our study 
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Table 7: Multiple logistic regression of significant variables 
Variables Not adherent Adherent 
OR  
(p-values) 
Region of residence    
North  185 315 
1.67 (<0.001)** 
West 130 370 
Level of Education   
Schooled women 216 600 
0.31 (<0.001)** 
unschooled 98 86 
Civil status   
Married  62 413 
0.16 (<0.001)** Not married (single, divorced and widows) 
 
252 273 
Matrimonial regime (for those married only)   
Polygamy 42 187 
2.54 (<0.001)** 
Monogamy 20 226 
Disclosure of serological status with the 
spouse/boyfriend and the family 
  
Yes 178 656 
0.12 (<0.001)** 
No 60 26 
Number of HIV-infected children   
More than one 1 28 
0.10 (0.002)** 
0 or 1 187 537 
Frequency of daily uptake of ARVs   
One-time 186 620 
0.15 (<0.001)** 
Twice  128 66 
Immunological status   
CD4 > 350 cells/mm3 29 110 
0.53 (0.002)** 
CD4 < 350 cells/mm3 285 576 
Viral load   
Undetectable (<40 copies/ml) 24 97 
0.5 (0.001)** 
Detectable (>40 copies/ml) 290 589 
 
After multivariate analysis using multiple logistic regression; 
having one HIV-infected children (aOR=60.9; 95%CI=[7.6; 
489.1]; P=0.001), non-disclosure of serological status with the 
spouse/boyfriend (aOR=25.2; 95%CI=[9.2; 68.9]; P<0.001), 
not being educated (aOR=7.7; 95%CI=[4.4; 13.3]; P<0.001); 
and taking ARVs once or less daily (aOR=50; 95%CI=[20.0; 
100.0]; P<0.001) were four risk factors for non-adherence 
(see table 8). 
 











Region of residence (West vs. 
North) 
0.7 [0.4; 1.2] -0.36 0.26 0.16 
Disclosure of the status (No vs. Yes) 25.2 [9.2;  68.9] 3.22 0.51 < 0.001** 
Daily arvs uptake (One or less vs 
more than one) 
50.0 [20.0;  100.0] -3.74 0.39 < 0.001** 
Number of HIV-infected children 
(more than one vs. one) 
60.9 [7.6;  489.1] 4.11 1.06 0.001** 
Level of education (wasn’t schooled 
vs. Schooled) 
7.7 [4.4; 13.3] 2.03 0.28 < 0.001** 
Civil status (unmarried vs. 
married) 
1.6 [0.9; 2.6] 0.46 0.25 0.06 
CD4 count (>350 vs. <350 
cells/mm3) 
0.8 [0.2; 3.6] -0.20 0.76 0.78 
Viral load (<40 vs. >40 RNA 
copies/ml) 
0.3 [0.06;  1.9] -1.03 0.84 0.22 
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DISCUSSION 
This study conducted among HIV-positive pregnant women 
under option B+ in the regions of North and West Cameroon 
aimed to identify the determinants of therapeutic adherence. 
Indeed, achieving the WHO goal of eliminating all vertical 
transmission of HIV remains a dilemma in resource-limited 
countries including Cameroon. The main objective of PMTCT 
interventions is to reduce barriers at each step of the 
continuum of care to successfully prevent vertical 
transmission of HIV. Despite the adoption of Option B+ and 
the combination of ARV delivery services at antenatal clinics, 
these barriers remain problematic for mother-child couples.  
Our results thus reveal an overall adherence level of 68.6%, 
i.e. 74.2% and 63% for the Northern and Western regions 
respectively. A much lower prevalence has been reported in 
Nigeria 15 where only 32.7% of HIV-positive pregnant 
women under option B+ reported 100% ART consumption 
over a four-day booster period. Another study in Tanzania 
reported low adherence of 26.3% and 61.1% among 
respondents living in urban and rural settings, respectively 
17. However, this is far below the 81.4% 18, 87.1% 14 and 89% 
19 found in northern Ethiopia and Kenya by other studies. 
Despite the differences observed among these African 
settings these figures are still far below the 95% 
recommended in order to ensure a zero risk of infection of 
the virus in newborns but also to prevent the occurrence of 
resistance. 
No association between age and ART adherence was found in 
our study. Similar results have also been obtained by many 
other studies documented that found no association between 
maternal age and ART adherence 20,21. 
As in many previous studies conducted in sub-Saharan 
Africa, sharing HIV status with one's spouse proved to be a 
real facilitator of adherence in pregnant women (p=0.0001), 
decreasing the probability of adherence by up to 4.88 times 
in those whose status remained unknown to the spouse. A 
similar result was found by Ebuy, H., Yebyo et al in Ethiopia 
where disclosure of HIV status was positively associated 
with good adherence increasing up to 4.2 times among 
women who had disclosed their status to their spouses 14. 
According to WHO globally, pregnant women in sub-Saharan 
Africa have the lowest rate of disclosure of HIV status 22. Fear 
of sharing HIV status with partners, family or community 
remains a major barrier to treatment adherence and use of 
PMTCT services 2,15,23,24. In the same logic, the daily 
frequency of ARV use emerges as an element influencing 
therapeutic adherence. Indeed, women who had to take their 
medication twice a day were less adherent (p=0.0001) than 
those who were entitled to a single dose. Indeed, it is more 
difficult to have to hide twice a day to take a medication with 
someone who shares our daily life night and day and/or to 
miss doses if we do not have the support of a spouse. A 
review conducted in 2014 by Hodgson, reveals that sharing 
status with one's spouse and being able to benefit from his or 
her support and participation throughout pregnancy 
significantly improves women's adherence and retention 
during the PMTCT program 25. The need to further mobilize 
male involvement in PMTCT programs is essential over time 
if we are to increase women's adherence to antiretroviral 
therapy and also eliminate vertical transmission of HIV.  
Women's education level is identified in our study as 
influencing adherence to antiretroviral therapy. Indeed, 
women with higher education levels were 5.43 (P-
value<0.0001) times more adherent compared to women 
with no education. A similar result was found by Tarekegn et 
al. in 2019 in a study of pregnant women on antiretroviral 
therapy in six public health facilities in Ethiopia. In this 
study, a significant association was found between 
educational attainment and adherence to ART; women with 
at least primary education were five times more likely to 
adhere to ART than those who could not read or write [OR 
4.54 (95% CI; 1.72-11.95)] 3. Similarly, many other studies 
have made the same finding 2,15. 
In our study, an association between multiparity and 
therapeutic adherence was found. Indeed, women with more 
than 4 children were more adherent than those with fewer 
children. Similar results were obtained in Zimbabwe 26 and 
Nigeria 27. This could be explained by the fact that the latter 
had already been enrolled in the PMTCT program at least 
once in a previous pregnancy and had been satisfied with the 
services and outcome due to the negative serological status 
of their children. As a result, they were more willing to 
adhere to the program than those who had been enrolled for 
the first time. This finding was also found by Murithi et al, in 
a study conducted in Kenya 28. Also in a study conducted in 
Uganda in 2017, some mothers reported discontinuing ART 
after losing their babies or even after delivery or when they 
stopped breastfeeding. Health workers in PMTCT services 
therefore have a dual responsibility to sensitize women on 
the importance of adherence to ART during and after 
pregnancy and even after weaning and adherence to 
medically prescribed dosages 29. The commitment and 
adherence of expectant mothers who are enrolled in the 
program will depend on the effectiveness of the results 
obtained.  
Limitation of this study includes selection bias on the field or 
the fact that we did not use a robust model in 
multiregression analysis. 
CONCLUSION 
This study was meant to establish a relationship between the 
socio-cultural and biological parameters and the 
determinants of non-adherence to ARVs among a PMTCT 
cohort. Indeed, the cohort of women included in this study 
came from two regions with totally different cultures and 
behaviors. Only 4 parameters were more or less strongly 
statistically significant as regards non-adherence after multi-
regression analysis. These results suggest that effective 
prevention of non-adherence among PMTCT women should 
take into consideration strategies to encourage disclosure of 
serological status among close relatives, women’s education 
and ART involving one-time drugs uptake per day. Also, as 
we are progressively moving towards the elimination of HIV 
vertical transmission in 2030 as advocated by UNAIDS, all 
barriers to the continuum of care should be identify and 
tackle adequately according to local sets. 
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